SFA
PCSA icon

Sequoia Financial Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Sequoia Financial Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-440
Closed -$2.25K – 1794
2025
Q2 		$2.25K Buy
+440
New +$2.94K ﹤0.01% 1581

Other funds holding PCSA

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
MMA
Miracle Mile Advisors Los Angeles, California $8.53B AUM 21.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Sequoia Financial Advisors's PCSA Position: Q3 2025 in Review

Sequoia Financial Advisors sold out of Processa Pharmaceuticals (PCSA) in Q3 2025, closing a stake of 440 shares — an estimated $2.25K sold.

Sequoia Financial Advisors first reported a position in PCSA in Q2 2025 and held it in 1 quarter. The position peaked at $2.25K in Q2 2025. 13 funds tracked by Wall St. Rank hold PCSA as of Q3 2025.

  • Sequoia Financial Advisors reported no remaining Processa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sequoia Financial Advisors sold 440 Processa Pharmaceuticals shares in Q3 2025, an estimated $2.25K.
  • Sequoia Financial Advisors first reported a position in Processa Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Sequoia Financial Advisors's Processa Pharmaceuticals position peaked at $2.25K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2025.

Based on Sequoia Financial Advisors's 13F filing for Q3 2025, filed 29 Oct 2025.